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Summary
 Introduction—Metabolic factors may contribute to osteoarthritis (OA).This study employed 
metabolomics analyses to determine if differences in metabolite profiles could distinguish people 
with knee OA who exhibited radiographic progression.
 Methods—Urine samples obtained at baseline and 18 months from overweight and obese 
adults in the Intensive Diet and Exercise for Arthritis (IDEA) trial were selected from two 
subgroups (n=22 each) for metabolomics analysis: a group that exhibited radiographic progression 
(≥ 0.7mm decrease in joint space width, JSW) and an age, gender, and BMI matched group who 
did not progress (≤0.35mm decrease in JSW). Multivariate analysis methods, including orthogonal 
partial least square discriminate analysis, were used to identify metabolite profiles that separated 
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progressors and non-progressors. Plasma levels of IL-6 and C-reactive protein were evaluated as 
inflammatory markers.
 Results—Multivariate analysis of the binned metabolomics data distinguished progressors 
from non-progressors. Library matching revealed that glycolate, hippurate, and trigonelline were 
among the important metabolites for distinguishing progressors from non-progressors at baseline 
whereas alanine, N,N-dimethyglycine, glycolate, hippurate, histidine, and trigonelline, were 
among the metabolites that were important for the discrimination at 18 months. In non-
progressors, IL-6 decreased from baseline to 18 months while IL-6 was unchanged in progressors; 
the change over time in IL-6 was significantly different between groups.
 Conclusion—These findings support a role for metabolic factors in the progression of knee 
OA and suggest that measurement of metabolites could be useful to predict progression. Further 
investigation in a larger sample that would include targeted investigation of specific metabolites is 
warranted.
 Introduction
Risk factors for osteoarthritis (OA) include age, obesity, prior joint injury, joint shape, and 
genetics1. Concerning body mass index (BMI) as a risk factor, a recent meta-analysis found 
a pooled odds ratio for knee OA of 2.02 for overweight adults (BMI 27–29.9 kg/m2) and 
3.91 for obese adults (BMI ≥30 kg/m2)2. Weight loss studies also support a link between 
body weight and knee OA. Weight loss in overweight and obese women without OA is 
associated with a reduced risk of developing symptomatic knee OA3. In overweight and 
obese adults with established knee OA, diet-induced weight loss reduces pain and improves 
physical function4, 5 as well as reduces levels of systemic inflammatory mediators5, 6. The 
mechanisms by which excessive body weight contributes to the development or progression 
of OA are not well understood but are of increasing interest, in part due to the growing 
numbers of overweight and obese older adults worldwide.
Although the obesity-knee OA link is well established, it is not clear how much of this is due 
to the effects of greater body weight on joint loads, promotion of a pro-inflammatory state, 
or altered metabolism. In addition to knee OA, increased BMI is also associated with OA of 
the hips7 and the hands8, 9. Data from the Netherlands Epidemiology of Obesity (NEO) 
study show that BMI and fat mass were associated with both knee10 and hand OA9. The 
association of BMI and fat mass with hand OA in particular suggests that inflammatory and 
metabolic factors, rather than simply excessive joint loading, may be contributing to the 
higher risk of development of OA with obesity.
An association of fat mass with OA suggests that factors produced by adipose tissue, such as 
cytokines and adipokines, may promote OA. There are several cytokines and adipokines, 
such as IL-1β, IL-6, TNFα, and leptin, produced by adipose tissue that have been 
hypothesized to contribute to OA11, 12, although it is not known if elevated systemic levels 
of these factors directly impact joint tissues. Systemic metabolic changes that result from 
excessive adiposity may also contribute to OA. Studies suggesting a metabolic contribution 
to OA have shown links between OA and other obesity-related metabolic conditions 
including hypertension and diabetes13–15.
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The studies demonstrating that increased BMI is a risk factor for OA have been studies of 
incident or prevalent disease. The role that obesity and associated metabolic factors might 
play in the progression of established OA is less clear15. There is some evidence that lower 
extremity alignment influences the risk of radiographic progression, defined by joint space 
narrowing, in obese adults with OA such that an increased risk is seen in people with neutral 
or valgus but not varus alignment16, 17. If progression of OA in overweight and obese adults 
is mostly driven by biomechanics, then metabolic factors might be expected to be much less 
important in progression of OA than in the early development of the disease, though this is 
not yet known.
This study examines the association between metabolic and inflammatory factors and 
radiographic progression of knee OA, defined by joint space loss, in overweight and obese 
adults with established knee OA. We sought to determine if a profile of metabolites could be 
found that distinguished progressors from non-progressors. A few cross-sectional studies 
have reported a different metabolomic profile between individuals with and without knee 
OA18–20 but an association of metabolites with disease progression in people with 
established OA has not been reported.
 Methods
 Study Participants
The participants in this study were a subset of those enrolled in the Intensive Diet and 
Exercise for Arthritis (IDEA) trial. Details of the inclusion and exclusion criteria as well as 
the interventions have been previously published21 as have the main clinical outcomes5. 
Briefly, IDEA was a prospective, single-blind, randomized controlled trial that enrolled 454 
overweight and obese (27.0 ≤ BMI ≤ 40.5 kg/m2), older (age ≥ 55 yrs) adults with knee pain 
and radiographic evidence of tibiofemoral osteoarthritis (Kellgren Lawrence grade = 2 or 3). 
Participants were randomized to one of three 18-month interventions: intensive dietary 
weight loss-only; intensive dietary weight loss-plus-exercise; or exercise-only control. Knee 
X-rays and blood and urine samples used for the present study had been obtained at baseline 
and 18 (FU18) months.
 Radiographic measure of OA progression and selection of subjects
A decrease in joint space width was used as a measure of OA progression. A detailed 
description of the radiographic procedures used to measure joint space width in the IDEA 
study has been recently published22. In brief, bilateral, posteroanterior, weight-bearing, knee 
x-rays were obtained with the participants’ knees flexed at 15 degrees using a positioning 
device (Synaflexer), and the beam centered on the joint space. The minimum joint space 
width (mJSW) was measured in digitized radiographic images using an automated software 
application. Based upon superior responsiveness from prior analyses, we selected the 
JSWx=0.225 as the optimal location for the fixed coordinate JSW measure. Positioning 
accuracy was measured by examining the distance from the floor of the tibial plateau to the 
most proximal tibial rim. We defined malpositioning as a change in this distance of >2mm 
between the baseline and 18 month radiograph. For the present study malpositioned subjects 
were excluded. A radiographic “progressor” was defined as those exhibiting a decrease in 
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JSW of ≥ 0.7mm in the medial compartment from baseline to 18 months which was based 
on the OARSI-OMERACT definition of relevant radiological progression23. A “non-
progressor” was defined as a decrease in JSW of ≤0.35mm. Progressors and non-progressors 
were chosen based on meeting the radiographic criteria without regards to intervention 
group assignment.
From the subset of IDEA participants who had radiographs available at both baseline and 18 
months and met these criteria, we had 45 progressors and 150 non-progressors and from 
these selected 22 progressors who could be matched to 22 non-progressors for age, gender, 
and baseline BMI. The baseline KL scores did not differ significantly between the 
progressors and non-progressors (p=0.36). Because alignment may influence the risk of 
progression, we measured baseline alignment using the femur-tibia angle measure (method 
B) reported by McDaniel et al24. There was a difference in the mean baseline alignment 
angle but it was not significant due to the large variability (progressors 0.96±5.06, mean
±SD, non-progressors −1.46±3.78; p=0.08). The intervention group assignment for the non-
progressors included 11 participants in diet plus exercise, 10 in diet only, and 2 in exercise 
only, while the progressor group included 9 in diet plus exercise, 7 in diet only and 6 in 
exercise only. We have recently published the radiographic outcomes for the entire IDEA 
cohort that showed there was no difference among the three intervention groups in 
radiographic progression22.
 Blood and Urine samples
Blood and urine (second am void) were collected from all subjects in the early morning after 
a 10-hour fast. The 18-month samples were collected at least 24 hours after the last acute 
bout of exercise training and sampling was postponed (1–2 weeks after recovery from 
symptoms) in the event of an acute respiratory, urinary tract, or other infection. Samples 
were aliquoted and stored in cryovials at −80°C until analyzed.
 Analysis of inflammatory biomarkers
Interleukin-6 and high sensitivity C-reactive protein (CRP) were chosen as biomarkers of 
inflammation for the IDEA trial. Plasma IL-6 levels were measured using an ELISA assay 
and the results for the entire cohort have been published5. CRP was measured using an 
automated immunoanalyzer (IMMULITE; Diagnostics Products Corporation, Los Angeles, 
CA) and the results for the entire cohort have also been published25.
 Metabolomics analysis
Sample preparation, data acquisition, statistics, and pathway analysis were performed as 
previously described26–29. Briefly, each urine sample was prepared by mixing an aliquot 
(400 μL) of each of the study urine samples with 230 μL of D2O and 70 μL Chenomx 
Internal Standard solution (Chenomx, Edmonton, Alberta, Canada). In addition, phenotypic 
pooled urine samples were made by combining 200 μL aliquots from each of the study 
samples belonging to the same phenotype (progressors-baseline, progressors-follow up, non-
progressors-baseline, and non-progressors-follow up). A combined phenotypic pooled 
sample was also prepared by using 400 μL aliquot from each of the phenotypic pooled 
sample. Three 400 μL aliquots of each of the pooled urine samples (phenotypic and 
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combined) were prepared identical to the individual urine samples. Metabolomics data were 
acquired for each of the individual study samples and the pooled samples. 1H NMR spectra 
of urine samples were acquired on a Bruker Avance III 950 MHz NMR spectrometer using a 
1D NOESY presaturation pulse sequence (noesypr1d, Beckonert et al, 2007). NMR spectra 
were pre-processed using ACD NMR software (Advanced Chemistry Development, 
Toronto, ON, Canada). Spectral region of 0.20 to 10.00 ppm was binned27 into 228 
integrated segments (NMR bins) of ppm regions (0.04 ppm bucket width) after excluding 
water (4.65–5.00 ppm), urea (5.50–6.00 ppm), and imidazole (7.20–7.50 ppm) using 
Intelligent Bucketing Integration with a 0.04 ppm bucket width and a 50% looseness factor. 
Each of the NMR bin integrals was normalized to total integral of each of the spectrum.
 Statistical Analyses
Normalized binned NMR data were Pareto scaled by dividing the integral of each bin by the 
reciprocal of the square root of the standard deviation for the bin and centered prior to 
multivariate analysis. These pattern recognition methods are commonly used to analyze high 
dimensional multicollinear data such as metabolomics data30, 31. The advantage of these 
methods is that they reduce the dimensionality by creating new variables which are not 
correlated, and also allow for the data to be visualized28, 29. SIMCA 13 (Umetrics, Umeå, 
Sweden) was used to conduct the principal component analysis (PCA), orthogonal partial 
least squares (OPLS), and orthogonal partial least squares discriminant analysis (OPLS-DA). 
PCA is an unsupervised analysis (the outcome is not used in the analysis) which reduces 
dimensionality by projecting the data onto a new coordinate system that allows for 
visualizing any clustering in the data and identifying outliers31. The PCA scored plots of the 
data in the new coordinate system were inspected to ensure that the phenotypic pooled 
samples were tightly clustered in the center of phenotypic groups and that the pools of all 
individual study samples clustered in the center of all samples, a quality control method that 
is widely used in metabolomic studies32.
OPLS and OPLS-DA are supervised analyses for continuous and categorical outcomes 
respectively. OPLS-DA was used to determine the metabolites that were important for 
differentiating the progressors and non-progressors. Loadings plots and variable influence on 
projection (VIP) plots were inspected, and bins that had a VIP ≥ 1.0 with a jack-knife 
confidence interval that did not include 0 were determined to be important for differentiating 
the study groups. The VIP statistic summarizes the importance of the bin in differentiating 
the phenotypic groups31. OPLS was used to examine the relationship between the 
continuous outcomes (changes in IL-6 and joint space). All models used a 7-fold cross-
validation to assess the predictive variation of the model (Q2). Chenomx NMR Suite 7.7 
Professional software (Edmonton, Alberta, Canada), which has a concentration library of 
approximately 350 compounds, was used to match the signals in the identified bins to 
metabolites. Metabolic pathway analysis was performed using the MetaCore® module in 
GeneGo software (GeneGo, St. Joseph, MI).
Statistical analyses were conducted using SAS 9.4 (SAS Institute Inc, Cary, NC). Statistical 
tests for continuous variables were conducted using a two-sided t-test with the Satterthwaite 
correction for unequal variances. The chi-square test was used to test for differences in 
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gender, and the Fisher’s Exact test was used to test for differences in race due to small cell 
counts. In this exploratory metabolomics study, p-values < 0.05 were considered to be 
statistically significant and were not adjusted for multiple testing as described33,34.
 Results
Participant demographics are provided in Table 1. There were no differences between 
progressors and non-progressors by age, gender or race. Clinical outcome measures at 
baseline, 18 months, and change from baseline are presented in Table 2. BMI was not 
significantly different between progressors and non-progressors at baseline, 18 months, or 
18 months compared to baseline. Progressors had significantly higher (p=0.004) minimum 
joint space at baseline (mean=4.1mm, SD=2.0) compared to non-progressors (mean=2.4mm, 
SD=1.5). At 18 months, there was no difference between the groups (p=0.53). By design, 
progressors had significantly greater (p < .0001) decline over 18 months in joint space width 
(mean= −1.3mm, SD=0.7) than non-progressors (mean=0.1mm, SD=0.4).
Baseline CRP tended to be higher in non-progressors than progressors (p=0.049), but CRP at 
18 months was not statistically different between groups (p=0.66). Non-progressors also 
tended to have a larger decrease in CRP than progressors (p=0.052). IL-6 was not 
significantly different between groups at baseline or 18 months; however, the change in IL-6 
was significantly different (p=0.04) with the mean IL-6 for non-progressors decreasing 
(mean= −0.9pg/ml, SD =1.1) and progressors increasing (mean=0.1pg/ml, SD=1.8).
The binned metabolomics data of urine collected at baseline was analyzed using OPLS-DA, 
which is a commonly used method for high dimensional multicollinear data, such as 
metabolomics data, and allows for visualization of the data30, 31. OPLS-DA distinguished 
radiographic progressors from non-progressors (Figure 1). NMR bins that were deemed to 
be important (VIP ≥ 1.0 with a jack-knife confidence interval that did not include 0) for 
distinguishing progressors from non-progressors were library matched for metabolites. 
NMR signals that could not be library matched were classified as unknown. Collectively, 
glycolate, hippurate, trigonelline, and two unknowns were important for differentiating 
progressors from non-progressors at baseline (Table 3).
Three of the 18 month follow up urine samples were found to be strong outliers in the PCA 
for the follow up samples (but not in the baseline samples) and high amounts of glucose 
were evident in the 1H NMR spectra of these samples and were excluded from further 
analysis of follow up data. Since these samples were not outliers at baseline they were 
included in the analysis for predicting OA progression. OPLS-DA distinguished progressors 
from non-progressors at the 18 month follow-up visit and library matching revealed 
differences in glycolate, hippurate, histidine, N,N-dimethylglycine, trigonelline, and two 
unknowns (Table 4). OPLS regression analysis showed that the baseline metabolomics data 
and the change in joint space width from baseline to 18 months were highly correlated in 
both progressors (R2=0.94, Q2=0.3, Figure 3) and non-progressors (R2=0.96, Q2=0.14, 
Figure 4). In addition, OPLS regression analysis showed that there was a greater correlation 
between the change in IL-6 and the baseline metabolomics data for non-progressors 
(R2=0.81, Q2=−0.28) than for progressors (R2=0.66, Q2=−0.69).
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Pathway enrichment analysis using the library-matched metabolites that distinguished OA 
progressors from non-progressors indicated that metabolic pathways related to amino acid 
metabolism, lipid metabolism, glycosphingolipid metabolism, and the GalNAcbeta1-3Gal 
pathway were perturbed. The amino acid metabolism pathways included alanine, glycine, 
cysteine metabolism and transport; alanine, serine, cysteine, methionine, histidine, proline, 
glycine, glutamate, glutamine metabolism and transport; tryptophan metabolism and 
transport, the glycine pathway; glycine pathways and transport; and the (L)-alanine 
pathways and transport.
 Discussion
There is mounting evidence that metabolic factors are important contributors to a host of 
conditions associated with obesity including OA13, 14, 35, 36. The association of obesity and 
metabolic factors with disease has been explained, at least in part, to associated systemic 
inflammation or “metainflammation” stemming from inflammatory mediators produced by 
an increased fat mass37, 38. Findings from the IDEA study have shown that an exercise and 
weight loss intervention in overweight and obese adults with knee OA improved pain and 
function in association with a reduction in fat mass as well as systemic inflammatory 
markers including IL-6 and CRP5, 25. In the present study, using urine samples from a sub-
set of IDEA participants, we found that differences in urine metabolites correlated with 
radiographic progression of knee OA and this correlation was much stronger than with the 
two measures of inflammation. Interestingly, NMR metabolomics at both baseline and at the 
18-month follow-up distinguished progressors from non-progressors who were matched for 
baseline BMI and who did not exhibit significant differences in BMI at 18 months, 
suggesting that differences in metabolism between the two groups contributed to the 
progression of their OA rather than simply a change in BMI.
It is important to note that the urine samples used for the metabolomics analysis were from 
IDEA participants selected based on meeting the radiographic criteria of disease 
progression, independent of intervention group assignment, with matching by age, gender, 
and baseline BMI to participants who met the criteria defined for the “non-progressor” 
group. Progressors (n=22) and non-progressors (n=22) were fairly evenly distributed among 
intervention groups, and analysis by intervention group could not be performed due to 
sample size constraints. For the full cohort, we recently reported22 that the radiographic 
measures of disease progression did not differ by intervention group assignment suggesting 
that the differences in the metabolite profiles between progressors and non-progressors were 
likely due to factors separate from the intervention group assignment. The finding that the 
non-progressors had a decrease in plasma IL-6 levels over the course of the study while the 
progressors had an increase suggests an association of progression with systemic 
inflammation and is consistent with a prior study that reported a positive association 
between IL-6 levels and development of knee OA39. A study with a larger sample size 
would be needed to determine if the change in IL-6 correlates with a change in 
metabolomics.
All prior metabolomic studies in humans have been cross-sectional in nature comparing 
individuals with or without OA using either urine18, 40, serum19, synovial fluid41 or 
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plasma20. An NMR-based urine metabolomics study that used samples from the Johnston 
County Osteoarthritis project found differences in participants with radiographic hip or knee 
OA from controls and noted a correlation of a metabolite profile with radiographic OA 
severity18. The NMR signals were not fully characterized (no mass spectroscopy was 
performed), but the NMR patterns suggested higher levels of hydroxybutyrate, pyruvate, 
creatine/creatinine and glycerol and lower levels of histidine and methylhistidine in those 
with OA relative to those without OA. We found that progression of joint space narrowing in 
adults with OA is associated with a different pattern of metabolites that included baseline 
levels of glycolate, hippurate, trigonelline, and at 18 months glycolate, hippurate, histidine, 
N,N-dimethylglycine, and trigonelline.
A more targeted approach using mass spectrometry to measure ratios of specific metabolites 
in serum noted that the ratios of branched-chain amino acids to histidine were significantly 
associated with knee OA when compared to healthy controls19. In a similar approach using 
plasma samples, patients with knee OA were found to have lower levels of arginine20. 
Finally, a metabolomics study that examined serum samples from healthy controls and 
patients with osteoarthritis, rheumatoid arthritis (RA), ankylosing spondylitis and gout, 
found that the patients with arthritis could be differentiated from the controls and that each 
form of arthritis had a distinct metabolite profile42.
Other studies have examined the profile of metabolites in synovial tissue or synovial fluid 
from subjects with knee OA. Adams et al43 analyzed conditioned media from cultures of 
synovial explants obtained from early and end-stage OA joints and noted differences in 
metabolites associated with collagen degradation, amino acid and branched-chain amino 
acid catabolism, energy metabolism and lipid and carbohydrate metabolism. Metabolic 
profiling using synovial fluid collected from 55 knee OA patients and 13 cadaveric controls, 
revealed 11 metabolites that separated the two groups41. None of the 11 metabolites 
identified in synovial fluid matched those found in the urine samples from our progression 
study or those found in plasma samples from a cross-sectional study of knee OA20.
Although these previous studies were cross-sectional and could not associate metabolic 
differences with OA progression, like our study they do support a role for metabolic factors 
in the development and progression of OA. Differences in the methodologies used for 
analysis, as well as the different patient populations studied, source of samples, and how the 
results were reported, preclude a direct comparison of specific metabolite profiles associated 
with OA in these studies and our own. In general, there was evidence that OA may be 
associated with differences in amino acid and collagen metabolism, the TCA cycle, and fatty 
acid metabolism. Our finding that hippurate and trigonelline, potential gut-flora derived 
metabolites44, differed between progressors and non-progressors suggests that differences in 
the gut microbiome could also be contributing to metabolic differences associated with OA 
progression.
There are several limitations of the present study. We were not able to include a replication 
cohort because of an insufficient number of radiographic progressors in the IDEA cohort to 
use for replication of the original metabolomics analysis and we did not have access to urine 
samples from an independent cohort of overweight and obese older adults with knee OA that 
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would meet the radiographic progression criteria we used here. Also due to the limited 
number of progressors, we included participants independent of the intervention group 
assignment and did not have sufficient numbers in each group to analyze for an intervention 
effect on the metabolites.
In summary, our finding that profiles of metabolites could distinguish overweight and obese 
adults with knee OA who exhibited radiographic progression from those who did not 
experience progression supports a role for metabolic factors in the progression of OA. These 
results also suggest that measurement of metabolites that include amino acids and lipids may 
be useful for evaluation of the efficacy of interventions for OA, as was recently reported for 
metabolic profiling predicting the response to anti-TNFα therapy in patients with RA45. Our 
results merit further investigation in a larger sample set including targeted analysis of 
identified marker metabolites.
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Fig. 1. 
Scores Plot of OPLS-DA showing separation of progressors (blue circles, right) from non-
progressors (green circles, left) at baseline [R2X = 0.2; R2Y= 0.5; Q2=−0.2].
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Fig. 2. 
Scores Plot of OPLS-DA showing separation of progressors (blue circles, right) from non-
progressors (green circles, left) at follow up visit after 18 months [R2X = 0.9; R2Y= 1.0; 
Q2=−0.5].
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Fig. 3. 
Plot of observed decrease in joint space width (JSW) from baseline to 18 months vs 
predicted decrease in JSW using OPLS regression of baseline metabolomics data for OA 
progressors. [R2=0.94, Q2=0.3]
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Fig. 4. 
Plot of observed decrease in joint space width (JSW) from baseline to 18 months vs 
predicted decrease in JSW using OPLS regression of baseline metabolomics data for OA 
non-progressors [R2=0.96, Q2=0.1].
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Table 1
Baseline Demographics
Characteristic Progressors (n=22) Non-Progressors (n=22) p-value
Age, mean (SD), years 66.5 (5.3) 66.4 (5.3) 0.94*
Gender
 Female 15 (68.2%) 15 (68.2%)
1.0**
 Male 7 (31.8%) 7 (31.8%)
Race/Ethnicity
 Caucasian 18 (81.8%) 19 (86.4%)
1.0†
 African American 4 (18.2%) 3 (13.6%)
SD, standard deviation;
*
t-test with Satterthwaite correction,
**Chi-Square Test,
†
Fisher’s Exact Test
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Table 3
Bins and library matched metabolites that distinguished progressors from non-progressors at baseline.
NMR Bin Library Matched Metabolite(s) VIP P-value Fold Change*
[1.49 .. 1.52] Unknown A 1.7 0.097 −1.4
[3.95 .. 4.00] Hippurate, Glycolate 3.0 0.182 1.2
[4.12 .. 4.15] Unknown B 1.5 0.041 −1.1
[4.39 .. 4.44] Trigonelline 1.7 0.036 −1.2
[8.55 .. 8.60] Hippurate 1.6 0.134 1.8
*
Positive fold change means the peak intensity of progressors is higher than non-progressors.
VIP: variable influence on projection
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Table 4
Bins and library matched metabolites that distinguished progressors from non-progressors at the 18 month 
follow up visit.
NMR Bin Library Matched Metabolite(s) VIP P-value Fold Change*
[1.45 .. 1.49] Alanine 1.2 0.624 −1.3
[1.73 .. 1.79] Unknown C 1.4 0.193 −1.1
[2.88 .. 2.93] N,N-Dimethylglycine 1.5 0.202 −1.1
[3.95 .. 4.00] Hippurate, Glycolate 4.8 0.043 1.3
[4.39 .. 4.44] Trigonelline 1.6 0.026 −1.3
[7.14 .. 7.16] Histidine 1.1 0.016 1.3
[7.28 .. 7.32] Unknown D 7.9 0.023 −4.6
[8.55 .. 8.60] Hippurate 1.4 0.159 2.4
*
Positive fold change means the peak intensity of progressor is higher than non-progressors.
VIP: variable influence on projection
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